Key facts
- It has raised $2.5M; the latest was Accelerator/Incubator in Jun 2025.
- Notable investors include Creative Destruction Lab, US National Science Foundation, MassChallenge, Startupbootcamp Holding, Connecticut Innovations — 18 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 18 names
- ·Watchlist + deal alerts for Encapsulate
- ·The full record, as it builds
Funding rounds
No funding rounds for Encapsulate are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Encapsulate
Developer of an automated tumor-on-a-chip technology designed to grow patients' cancer cells outside the body. The company's technology uses cancer cells during initial cancer diagnosis and is grown and preserved as microtumors, which are used to evaluate the efficacy of chemotherapeutic or biotherapeutic drugs on an individualized basis, enabling oncologists to understand which treatments are likely to work for a specific patient's tumour.
- Sector
- Healthcare
- HQ
- Farmington, CT, United States
- Founded
- 2018
- Employees
- 10
- Website
- encapsulate.bio/
- Ownership
- Privately Held (backing)
Encapsulate doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Encapsulate shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Encapsulate in its N-PORT filings yet. We sweep new filings monthly.